The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Subscribe To Our Newsletter & Stay Updated
